

David S Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6326936/publications.pdf>

Version: 2024-02-01

258
papers

9,443
citations

41344

49
h-index

46799

89
g-index

268
all docs

268
docs citations

268
times ranked

8197
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3113-3119.	1.6	520
2	Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 4626-4633.	1.6	484
3	Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 437-448.	27.0	375
4	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 636-648.	10.7	366
5	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	4.9	356
6	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2317-2326.	27.0	326
7	Epigenetic Repression of <i>microRNA-129-2</i> Leads to Overexpression of <i>SOX4</i> Oncogene in Endometrial Cancer. <i>Cancer Research</i> , 2009, 69, 9038-9046.	0.9	262
8	Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 12-12.	1.6	255
9	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1810-1818.	1.6	229
10	Somatic LKB1 Mutations Promote Cervical Cancer Progression. <i>PLoS ONE</i> , 2009, 4, e5137.	2.5	229
11	Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 125, 771.	1.4	214
12	Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 2686-2691.	1.6	163
13	Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. <i>Human Molecular Genetics</i> , 1998, 7, 195-202.	2.9	158
14	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020, 38, 3841-3850.	1.6	155
15	The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline. <i>Practical Radiation Oncology</i> , 2014, 4, 137-144.	2.1	151
16	Intraoperative Lymphatic Mapping in Cervix Cancer Patients Undergoing Radical Hysterectomy: A Pilot Study. <i>Gynecologic Oncology</i> , 2000, 79, 238-243.	1.4	146
17	Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 825-831.	1.6	139
18	Tumor size in endometrial cancer. <i>Cancer</i> , 1991, 67, 2791-2794.	4.1	120

#	ARTICLE	IF	CITATIONS
19	Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas. <i>Obstetrics and Gynecology</i> , 2005, 106, 1304-1308.	2.4	94
20	CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1831-1834.	3.6	91
21	A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2002, 87, 247-251.	1.4	86
22	Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 3474-3478.	7.0	85
23	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 174-180.	1.4	83
24	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015, 125, 4063-4076.	8.2	79
25	Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on multivariate analysis. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 611-616.	1.3	76
26	CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1831-1834.	3.6	74
27	Adenovirus-Based p53 Gene Therapy in Ovarian Cancer. <i>Gynecologic Oncology</i> , 1995, 59, 171-178.	1.4	73
28	New therapies for advanced, recurrent, and metastatic endometrial cancers. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 19.	3.6	72
29	A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 441-445.	1.4	69
30	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
31	Flow cytometric evaluation of epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 1584-1592.	1.3	66
32	A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 464-471.	0.8	66
33	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	1.6	61
34	Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. <i>Cancer</i> , 1992, 69, 502-510.	4.1	60
35	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 178-188.	0.8	60
36	Stage IIB to IVB Cervical Adenocarcinoma: Prognostic Factors and Survival. <i>Gynecologic Oncology</i> , 2002, 84, 115-119.	1.4	58

#	ARTICLE	IF	CITATIONS
37	Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2005, 98, 217-221.	1.4	58
38	Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. <i>Obstetrics and Gynecology</i> , 2016, 128, 535-542.	2.4	58
39	A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5505-5505.	1.6	58
40	Endocervical Curettage at Conization to Predict Residual Cervical Adenocarcinoma in Situ. <i>Gynecologic Oncology</i> , 2002, 87, 129-132.	1.4	56
41	Phase II Trial of Topotecan in Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 355-357.	1.3	56
42	Pulsatile Administration of Low-Dose Gonadotropin-Releasing Hormone. <i>JAMA - Journal of the American Medical Association</i> , 1983, 250, 2937.	7.4	55
43	Oral dexamethasone attenuates Doxil [®] -induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. <i>Gynecologic Oncology</i> , 2004, 94, 320-324.	1.4	55
44	Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2008, 110, 65-70.	1.4	55
45	Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. <i>Gynecologic Oncology</i> , 2003, 91, 558-562.	1.4	54
46	Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2004, 92, 639-643.	1.4	53
47	Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 575-582.	1.4	53
48	Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. <i>Gynecologic Oncology</i> , 2017, 145, 519-525.	1.4	52
49	A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. <i>Cancer</i> , 2004, 100, 859-868.	4.1	51
50	Gestational trophoblastic disease among Hispanic women: A 21-year hospital-based study. <i>Gynecologic Oncology</i> , 2006, 103, 81-86.	1.4	51
51	Fertility-sparing surgery for ovarian low malignant potential tumors. <i>Gynecologic Oncology</i> , 2005, 98, 263-266.	1.4	50
52	A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. <i>Cancer</i> , 1986, 57, 530-535.	4.1	49
53	Abnormalities of Fragile Histidine Triad Genomic and Complementary DNAs in Cervical Cancer: Association With Human Papillomavirus Type. <i>Journal of the National Cancer Institute</i> , 1998, 90, 433-439.	6.3	49
54	P16 as a molecular biomarker of cervical adenocarcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 668-673.	1.3	49

#	ARTICLE	IF	CITATIONS
55	Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 674-679.	1.3	47
56	Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies. <i>Gynecologic Oncology</i> , 1990, 39, 72-79.	1.4	41
57	Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2002, 85, 507-510.	1.4	41
58	A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 127, 456-461.	1.4	40
59	Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. <i>Gynecologic Oncology</i> , 2007, 107, 316-319.	1.4	39
60	A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 121, 118-121.	1.4	39
61	Implications of EGFR inhibition in ovarian cancer cell proliferation. <i>Gynecologic Oncology</i> , 2008, 109, 411-417.	1.4	38
62	A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1313.	0.8	38
63	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 968-977.	1.6	38
64	Endometrial Endometrioid Carcinomas Associated with Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 127-132.	1.4	37
65	Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells. <i>Reproductive Sciences</i> , 2007, 14, 20-28.	2.5	37
66	Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2010, 117, 239-247.	1.4	37
67	A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes. <i>Journal of Clinical Oncology</i> , 2013, 31, 5520-5520.	1.6	37
68	Preinvasive and Invasive Breast and Cervical Cancer Prior to or During Pregnancy. <i>Clinics in Perinatology</i> , 1997, 24, 369-389.	2.1	36
69	Pathology Slide Review in Gynecologic Oncology. <i>Obstetrics and Gynecology</i> , 1998, 91, 730-734.	2.4	36
70	Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1 <i>Gynecologic Oncology</i> , 2006, 100, 537-543.	1.4	36
71	The Ovarian Tumor Index predicts risk for malignancy. , 1999, 86, 2280-2290.		35
72	Localized Retroperitoneal Lymphangioliomyomatosis Mimicking Malignancy. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 879-882.	2.5	35

#	ARTICLE	IF	CITATIONS
73	Chromosome 4 Deletions Are Frequent in Invasive Cervical Cancer and Differ between Histologic Variants. <i>Gynecologic Oncology</i> , 2000, 79, 90-96.	1.4	34
74	A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology. <i>Gynecologic Oncology</i> , 2009, 115, 443-446.	1.4	34
75	Surgical and systemic management of endometrial cancer: an international survey. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 897-905.	1.7	34
76	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1050-1060.	3.7	34
77	A Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1992, 15, 125-128.	1.3	33
78	Brachial Plexus Palsy and Shoulder Dystocia: Obstetric Risk Factors Remain Elusive. <i>American Journal of Perinatology</i> , 2013, 30, 303-308.	1.4	33
79	Malignant ovarian germ cell tumor " Role of surgical staging and gonadal dysgenesis. <i>Gynecologic Oncology</i> , 2014, 134, 84-89.	1.4	33
80	Frequent Expression of β -Human Chorionic Gonadotropin (β -hCG) in Squamous Cell Carcinoma of the Cervix. <i>International Journal of Gynecological Pathology</i> , 1999, 18, 381-386.	1.4	32
81	Ovarian involvement in endometrioid adenocarcinoma of uterus. <i>Gynecologic Oncology</i> , 2015, 138, 532-535.	1.4	32
82	In Vivo Studies of Adenovirus-Based p53 Gene Therapy for Ovarian Cancer. <i>Gynecologic Oncology</i> , 1998, 69, 197-204.	1.4	31
83	Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 242.e1-242.e5.	1.3	31
84	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. <i>Gynecologic Oncology</i> , 2016, 143, 294-301.	1.4	31
85	Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. <i>Journal of the Society for Gynecologic Investigation</i> , 1999, 6, 213-221.	1.7	31
86	Preoperative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 1020-1028.	1.7	30
87	A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naïve patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5500-5500.	1.6	29
88	Pathology Slide Review in Gynecologic Oncology. <i>Obstetrics and Gynecology</i> , 1998, 91, 730-734.	2.4	28
89	Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1362-1364.	1.3	28
90	The Role of Lymphadenectomy in Endometrial Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 235-244.	1.1	28

#	ARTICLE	IF	CITATIONS
91	A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, S4.	1.4	27
92	Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 533-542.	1.4	25
93	ZoptEC: Phase III randomized controlled study comparing zoletarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5503-5503.	1.6	25
94	DNA Flow Cytometric Analysis of Clinical Stage I Endometrial Carcinomas with Lymph Node Metastases. <i>Gynecologic Oncology</i> , 1993, 50, 20-24.	1.4	23
95	Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2020, 156, 423-429.	1.4	23
96	Beyond Sedlisâ€”A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. <i>Gynecologic Oncology</i> , 2021, 162, 532-538.	1.4	22
97	Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma. <i>Cancer</i> , 2003, 98, 1664-1669.	4.1	21
98	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	1.6	21
99	Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. <i>International Journal of Cancer</i> , 2018, 142, 1102-1115.	5.1	21
100	Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea. <i>JAMA - Journal of the American Medical Association</i> , 1983, 250, 2937-2941.	7.4	21
101	Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2005, 96, 67-71.	1.4	19
102	Sparse feature selection for classification and prediction of metastasis in endometrial cancer. <i>BMC Genomics</i> , 2017, 18, 233.	2.8	19
103	Long-Term Percutaneous Nephrostomy Management of Malignant Urinary Obstruction: Estimation of Optimal Exchange Frequency and Estimation of the Financial Impact of Patient Compliance. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1036-1042.e8.	0.5	19
104	GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study. <i>Gynecologic Oncology</i> , 2018, 149, 2.	1.4	19
105	QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received â‰¥3 prior chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5514-5514.	1.6	19
106	A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. <i>Gynecologic Oncology</i> , 2022, 164, 481-491.	1.4	19
107	Pharmacotherapy of endometrial cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1939-1951.	1.8	18
108	The Significance of Macrocephaly or Enlarging Head Circumference in Infants With the Triad. <i>American Journal of Forensic Medicine and Pathology</i> , 2015, 36, 111-120.	0.8	18

#	ARTICLE	IF	CITATIONS
109	726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). <i>Annals of Oncology</i> , 2021, 32, S729-S730.	1.2	18
110	Transfusion Medicine in Obstetrics and Gynecology. <i>Obstetrical and Gynecological Survey</i> , 1995, 50, 470-481.	0.4	18
111	Classification and Staging of Gestational Trophoblastic Tumors. <i>Obstetrics and Gynecology Clinics of North America</i> , 1988, 15, 477-490.	1.9	18
112	Postmolar surveillance at a trophoblastic disease center that serves indigent women. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 1151-1153.	1.3	17
113	Hormonal therapy in epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 43-47.	2.4	17
114	Gynecologic oncology group trials in uterine corpus malignancies: recent progress. <i>Journal of Gynecologic Oncology</i> , 2008, 19, 218.	2.2	17
115	An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. <i>Gynecologic Oncology</i> , 2020, 158, 354-360.	1.4	17
116	Schistosomiasis and cervical cancer in Ghana. <i>International Journal of Gynecology and Obstetrics</i> , 1993, 42, 127-130.	2.3	16
117	Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 2744-2749.	1.6	16
118	Immunologic characterization of tumor markers in human ovarian cancer cell lines. <i>Journal of the Society for Gynecologic Investigation</i> , 1996, 3, 216-222.	1.7	16
119	A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 18-18.	1.6	16
120	Epithelial ovarian carcinoma in patients with intersex disorders: The role of pituitary gonadotropins in ovarian tumorigenesis. <i>Gynecologic Oncology</i> , 1986, 24, 299-308.	1.4	15
121	The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies. <i>Gynecologic Oncology</i> , 1995, 56, 250-254.	1.4	15
122	Adenomyofibroma of the Endometrium with Skeletal Muscle Differentiation. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 280-283.	1.4	15
123	Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2005, 96, 810-817.	1.4	15
124	A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study. <i>Gynecologic Oncology</i> , 2017, 145, 219.	1.4	15
125	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	1.0	15
126	The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1225-1230.	1.3	15

#	ARTICLE	IF	CITATIONS
127	A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1137-1141.	2.5	15
128	Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. <i>Gynecologic Oncology</i> , 2012, 127, 43-46.	1.4	14
129	Early-Stage Cervical Adenocarcinoma Treated by Surgical Intent: The Role of Para-aortic Lymph Node Dissection. <i>Gynecologic Oncology</i> , 2002, 84, 285-288.	1.4	13
130	Distinct microscopic features of perineural invasion in adenoid cystic carcinoma of the head and neck. <i>Histopathology</i> , 2014, 64, 1037-1039.	2.9	13
131	Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. <i>International Journal of Gynecology and Obstetrics</i> , 1993, 42, 94-95.	2.3	12
132	Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 365-372.	2.5	12
133	Uterine Metastasis from a Heterologous Metaplastic Breast Carcinoma Simulating a Primary Uterine Malignancy. <i>Gynecologic Oncology</i> , 2000, 77, 216-218.	1.4	11
134	Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, e20-e22.	1.3	11
135	Adenocarcinoma of the Uterine Corpus. , 2012, , 141-174.e6.		11
136	Ectopic Production and Localization of ??-Human Chorionic Gonadotropin in Lymphoepithelioma-Like Carcinoma of the Cervix: A Case Report. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 179-182.	1.4	11
137	Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients. <i>Obstetrics and Gynecology</i> , 2000, 96, 23-27.	2.4	10
138	Understanding the Mechanisms of FHIT Inactivation in Cervical Cancer for Biomarker Development. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 329-337.	1.7	10
139	The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. <i>Gynecologic Oncology</i> , 2017, 144, 586-591.	1.4	10
140	A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5524.	1.6	10
141	Does Glutamine Supplementation Increase Radioresistance in Squamous Cell Carcinoma of the Cervix?. <i>Gynecologic Oncology</i> , 1998, 71, 359-363.	1.4	9
142	Urinary Bladder Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2002, 45, 844-854.	1.1	9
143	Cervical adenocarcinoma survival among Hispanic and white women: A multicenter cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 640-644.	1.3	9
144	2A phase II study to determine the response to second curettage as initial management for persistent "low-risk" non-metastatic gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 134, 438-439.	1.4	9

#	ARTICLE	IF	CITATIONS
145	Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 933-937.	1.3	9
146	Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. Journal of Pathology, 2021, 254, 20-30.	4.5	9
147	Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).. Journal of Clinical Oncology, 2021, 39, 5570-5570.	1.6	9
148	A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.. Journal of Clinical Oncology, 2019, 37, TPS5607-TPS5607.	1.6	9
149	Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma. Gynecologic Oncology, 1991, 41, 22-27.	1.4	8
150	ABDOMINAL COMPARTMENT SYNDROME IN GYNECOLOGIC SURGERY. Obstetrics and Gynecology, 1999, 94, 830-832.	2.4	8
151	Germline BRCA1/2 Mutations in Non-Ashkenazi Families with Double Primary Breast and Ovarian Cancer. Gynecologic Oncology, 2001, 83, 383-387.	1.4	8
152	Advanced endometrial cancer: Is lymphadenectomy necessary or sufficient?. Gynecologic Oncology, 2006, 101, 191-193.	1.4	8
153	Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 792-796.	1.3	8
154	The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. Gynecologic Oncology, 2019, 154, 13-21.	1.4	8
155	Stigma, beliefs and perceptions regarding prostate cancer among Black and Latino men and women. BMC Public Health, 2021, 21, 758.	2.9	8
156	Abdominal compartment syndrome in gynecologic surgery. Obstetrics and Gynecology, 1999, 94, 830-832.	2.4	7
157	Factors associated with clinical trial screening failures in gynecologic oncology. Gynecologic Oncology, 2014, 134, 450-454.	1.4	7
158	Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery. Gynecologic Oncology Reports, 2020, 34, 100627.	0.6	7
159	Role of TSG101 in Uterine Cervix Cancer. Gynecologic Oncology, 1999, 75, 401-405.	1.4	6
160	Other primary malignancies in patients with uterine corpus malignancy. American Journal of Obstetrics and Gynecology, 2004, 190, 1429-1431.	1.3	6
161	Clinical applications of hormonal therapy in ovarian cancer. Current Treatment Options in Oncology, 2005, 6, 97-102.	3.0	6
162	Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1220-1224.	1.3	6

#	ARTICLE	IF	CITATIONS
163	Locally Advanced Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 447-451.	1.3	6
164	Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (â%¥4th line), advanced, recurrent high-grade serous ovarian cancer. Gynecologic Oncology, 2019, 154, 3.	1.4	6
165	Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group. Gynecologic Oncology, 2020, 157, 312-322.	1.4	6
166	Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 719-726.	2.5	6
167	Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. Modern Chemotherapy, 2013, 02, 19-32.	0.5	6
168	0008/#785â€...A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physicianâ€™s choice in patients with advanced endometrial cancer: study 309/keynote-775. , 2021, , .		6
169	Brief Note: Observations on a Case of Probable Bone Marrow Anthracosis. Blood, 1959, 14, 1350-1353.	1.4	5
170	Stage IVA cervical cancer: outcomes of disease related complications and treatment. International Journal of Gynecological Cancer, 2021, 31, 518-523.	2.5	5
171	Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.. Journal of Clinical Oncology, 2018, 36, 5505-5505.	1.6	5
172	Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecologic Oncology, 2022, 164, 428-436.	1.4	5
173	Chemo- and Radiotherapy in Adjuvant Management of Optimally Debulked Endometrial Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 535-541.	4.9	4
174	Should All Patients with Serous and Clear Cell Endometrial Carcinoma Receive Adjuvant Chemotherapy?. Women's Health, 2010, 6, 789-795.	1.5	4
175	Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. Gynecologic Oncology, 2012, 124, 508-511.	1.4	4
176	Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecologic Oncology, 2014, 134, 552-555.	1.4	4
177	Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery. Cancer, 2017, 123, 192-196.	4.1	4
178	QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAMut subset. Annals of Oncology, 2018, 29, viii337.	1.2	4
179	Practice patterns using minimally invasive surgery for the treatment of ovarian cancer: A survey of physician members of the Society of Gynecologic Oncologists. Gynecologic Oncology Reports, 2020, 33, 100617.	0.6	4
180	Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma: A Gynecologic Oncology Group/NRG study.. Journal of Clinical Oncology, 2018, 36, 5589-5589.	1.6	4

#	ARTICLE	IF	CITATIONS
181	Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	4
182	Reply to W.A.A. Tjalma and J.S. Grossman. <i>Journal of Clinical Oncology</i> , 2015, 33, 966-966.	1.6	3
183	Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1137-1141.	1.3	3
184	Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 797-801.	1.3	3
185	Current practice patterns in nodal evaluation and adjuvant treatment of advanced stage endometrioid endometrial cancer: An SGO survey. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100620.	0.6	3
186	Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5563-5563.	1.6	3
187	Clinical Evidence: Metastases can Metastasize. <i>World Journal of Oncology</i> , 2012, 3, 138-141.	1.5	3
188	Long-term results of interstitial implant in locally advanced cervical cancer:A retrospective study of 50 cases. <i>Radiation Oncology Investigations</i> , 1996, 4, 33-40.	0.9	2
189	Survival outcomes after recurrence in endometrioid compared to papillary serous/clear cell carcinoma of the uterus. <i>Gynecologic Oncology</i> , 2012, 127, S28.	1.4	2
190	A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) women with locally advanced cervical cancer (CXCA): A GOG study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5032-5032.	1.6	2
191	145â€...Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775).. , 2021, , .		2
192	Recent Progress: Gynecologic Oncology Group Trials in Uterine Corpus Tumors. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 70-74.	0.8	1
193	Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors. <i>Gynecologic Oncology</i> , 2011, 123, 445-446.	1.4	1
194	Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2013, 6, 42-45.	0.1	1
195	Core muscle index is prognostic of survival in advanced ovarian cancers. <i>Gynecologic Oncology</i> , 2016, 143, 206-207.	1.4	1
196	Adenocarcinoma of the Uterine Corpus. , 2018, , 121-154.e8.		1
197	Screening for Lynch syndrome in a medically underserved population. <i>Gynecologic Oncology</i> , 2018, 149, 143.	1.4	1
198	Prognostic factors associated with overall survival in presumed early stage, high-grade serous ovarian cancer: an analysis of the SEER cancer database. <i>Gynecologic Oncology</i> , 2021, 162, S246.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS. , 2019, , .		1
200	O002/#43â€¦Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors. , 2021, , .		1
201	Pulsatile Administration of Low-Dose Gonadotropin-Releasing Hormone. Ovulation and Pregnancy in Women with Hypothalamic Amenorrhea. Obstetrical and Gynecological Survey, 1984, 39, 296-297.	0.4	0
202	Critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. III. Factors associated with persistent disease-free status and recurrence after â€œnegativeâ€œ operation. Gynecologic Oncology, 1988, 29, 135.	1.4	0
203	Genetic Changes During the Multistage Pathogenesis of Human Papillomavirus Positive and Negative Vulvar Carcinomas. Journal of the Society for Gynecologic Investigation, 1999, 6, 213-221.	1.7	0
204	Bacteriology and Treatment of Malodorous Lower Reproductive Tract in Gynecologic Cancer Patients. Obstetrics and Gynecology, 2000, 96, 23-27.	2.4	0
205	Management of Low-Risk Gestational Trophoblastic Tumors in an Indigent Population. Obstetrics and Gynecology, 2002, 99, 92S.	2.4	0
206	Fertility-Sparing Surgery for Ovarian Low Malignant Potential Tumors. Obstetrical and Gynecological Survey, 2005, 60, 797-798.	0.4	0
207	Secreted protein rich and acidic in cysteine (SPARC) as a predictor of cervical carcinogenesis and regulator of cervical cancer growth. Gynecologic Oncology, 2007, 107, 361-362.	1.4	0
208	Multi-institutional retrospective analysis of lymphadenectomy in early stage adenocarcinoma of the cervix. Gynecologic Oncology, 2007, 107, 366-367.	1.4	0
209	PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2010, 3, 74-78.	0.2	0
210	PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2011, 4, 106-110.	0.2	0
211	Outcomes of third line chemotherapy for recurrent and persistent cervical cancer. Gynecologic Oncology, 2011, 123, 442-443.	1.4	0
212	Survival impact of clinical trials in patients with recurrent cervical cancer. Gynecologic Oncology, 2011, 123, 447-448.	1.4	0
213	Challenging prognostic factors for chemotherapy resistance in high-risk gestational trophoblastic neoplasia. Gynecologic Oncology, 2011, 123, 449.	1.4	0
214	Does myometrial invasion confer a poorer prognosis in uterine adenosarcoma?. Gynecologic Oncology, 2011, 123, 450.	1.4	0
215	Stage IIIC1 versus IIIC2 endometrial adenocarcinoma of the uterus: Analysis of recurrence and patterns of toxicity. Gynecologic Oncology, 2012, 127, S18-S19.	1.4	0
216	Clinical course of ovarian cancer after two salvage regimens. Gynecologic Oncology, 2012, 127, S27-S28.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Incidence of adnexal metastasis requiring surgical intervention in women with advanced cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, S33.	1.4	0
218	Challenging prognostic factors for chemotherapy resistance in gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2012, 125, S84.	1.4	0
219	Effect of BMI on progesterone therapy for endometrial cancer. <i>Gynecologic Oncology</i> , 2012, 125, S163.	1.4	0
220	Outcomes of phenotypic females with dysgerminoma and 46, XY karyotype. <i>Gynecologic Oncology</i> , 2013, 131, 257.	1.4	0
221	Cervical cancer " Distant failure after treatment of para-aortic lymph node metastases. <i>Gynecologic Oncology</i> , 2014, 135, 389.	1.4	0
222	Isolated ovarian metastasis in endometrial adenocarcinoma of uterus. <i>Gynecologic Oncology</i> , 2014, 135, 393.	1.4	0
223	Defining optimal management of midline vulvar cancers. <i>Gynecologic Oncology</i> , 2015, 139, 179.	1.4	0
224	Emphasis on systemic therapy for women with pelvic bone involvement at time of diagnosis of cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 200.	1.4	0
225	Adjuvant External Radiation is Essential in the Management of Pelvis-Limited Stage III Endometrial Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, S10-S11.	0.8	0
226	Locally advanced cervical cancer: Effect of radiation dosage and treatment duration on outcomes. <i>Gynecologic Oncology</i> , 2015, 139, 179-180.	1.4	0
227	Anti-angiogenic treatment of cervical cancer significantly decreases new target lesions. <i>Gynecologic Oncology</i> , 2015, 139, 196.	1.4	0
228	Factors influencing primary treatment of midline vulvar cancers. <i>Gynecologic Oncology</i> , 2016, 142, 133-138.	1.4	0
229	Weekly Paclitaxel for Recurrent Ovarian Cancer: Does Weekly Administration at Primary Diagnosis Impact Efficacy and Toxicity at Recurrence?. <i>Gynecologic Oncology</i> , 2016, 143, 204.	1.4	0
230	The Opinions and Practices of Providers Toward the Sexual Issues of Cervical Cancer Patients Undergoing Treatment. <i>Gynecologic Oncology</i> , 2016, 143, 211-212.	1.4	0
231	Prognostic Significance of Nodal Location in Stage IIIC Endometrial Carcinoma: Implications for Optimal Adjuvant Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E303.	0.8	0
232	Sparse Feature Selection for Classification and Prediction of Metastasis in Endometrial Cancer. , 2016, , .		0
233	Response to "Towards implementation of sexual healthcare". <i>Gynecologic Oncology Reports</i> , 2017, 20, 139.	0.6	0
234	Weekly paclitaxel for recurrent ovarian cancer: Does weekly administration during primary therapy impact efficacy and toxicity at recurrence?. <i>Gynecologic Oncology</i> , 2017, 145, 155.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Description of Medium- and Long-Term Complications After PCN Placement for Malignant Urinary Obstruction [1J]. <i>Obstetrics and Gynecology</i> , 2017, 129, 103S-103S.	2.4	0
236	Considering Closed Incision Negative Pressure Therapy for Obese Patients with Gynecologic Malignancies [31E]. <i>Obstetrics and Gynecology</i> , 2017, 129, 59S-60S.	2.4	0
237	Determination of Optimal Routine Exchange Frequency After PCN Placement for Malignant Urinary Obstruction [35E]. <i>Obstetrics and Gynecology</i> , 2017, 129, 60S-61S.	2.4	0
238	Detection of Chronic Hepatitis B in Gynecologic Oncology Patients Undergoing Systemic Chemotherapy. <i>Gynecologic Oncology</i> , 2017, 147, 207-208.	1.4	0
239	Family History of Cancer Shows Improved Survival in Uterine Papillary Serous Carcinoma. <i>Gynecologic Oncology</i> , 2017, 147, 225-226.	1.4	0
240	Patients with Sarcopenia Benefit from Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. <i>Gynecologic Oncology</i> , 2017, 147, 226.	1.4	0
241	Reply to F. Tomao et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 936-936.	1.6	0
242	Comparing overall survival in women diagnosed and treated for a gynecological sarcoma at a private versus county hospital. <i>Gynecologic Oncology</i> , 2020, 159, 247-248.	1.4	0
243	Association between elapsed time after initial diagnosis and outcomes in patients diagnosed with early stage cervical cancer at a safety net hospital. <i>Gynecologic Oncology</i> , 2020, 159, e9-e10.	1.4	0
244	Lynch Syndrome Identification in Endometrial Cancer Patients: Should Universal Screening be Used for all Histologies?. <i>Current Women's Health Reviews</i> , 2021, 17, .	0.2	0
245	Is there a need for consultant team for bowel resection? An evaluation of surgical outcomes of bowel resection at time of ovarian cytoreductive surgery. <i>Gynecologic Oncology</i> , 2021, 162, S193.	1.4	0
246	Delayed time to surgery with hormonal treatment does not adversely impact outcomes in women with low-grade endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, S124.	1.4	0
247	Risk factors associated with 30-day postoperative complications following contemporary pelvic exenterations for gynecologic cancer. <i>Gynecologic Oncology</i> , 2021, 162, S264-S265.	1.4	0
248	Perioperative risk factors and postoperative outcomes following pelvic exenterations for gynecologic versus non-gynecologic malignancies. <i>Gynecologic Oncology</i> , 2021, 162, S233-S234.	1.4	0
249	Stoma creation at the time of large bowel resection during ovarian cytoreductive surgery does not improve 30-day postoperative surgical outcomes. <i>Gynecologic Oncology</i> , 2021, 162, S278-S279.	1.4	0
250	The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.. <i>Journal of Clinical Oncology</i> , 2010, 28, 5122-5122.	1.6	0
251	Third-line salvage chemotherapy for recurrent cervical cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15510-e15510.	1.6	0
252	How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5087-5087.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Recurrence patterns in patients with stage IIC1 versus IIC2 endometrial adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, e15501-e15501.	1.6	0
254	Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.. Journal of Clinical Oncology, 2019, 37, 5509-5509.	1.6	0
255	Beyond Sedlis: A novel, histology-based nomogram for predicting recurrence risk and need for adjuvant radiation in cervical cancerâ€”A NRG/GOG ancillary analysis.. Journal of Clinical Oncology, 2020, 38, 6019-6019.	1.6	0
256	Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery.. Journal of Clinical Oncology, 2020, 38, e18046-e18046.	1.6	0
257	125â€¦Results of a randomized phase ii trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent chemo-naïve stromal ovarian tumors. , 2020, , .		0
258	Risk factors associated with 30-day postoperative complications following contemporary vulvectomies with inguinofemoral lymphadenectomies for gynecologic cancers. Gynecologic Oncology, 2022, 164, 2-3.	1.4	0